CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors' preferences ("Prometheus") in Russia - first results of the survey

• Autori principali: E. V. Artamonova (Autore), E. I. Kovalenko (Autore), L. V. Bolotina (Autore), M. B. Stenina (Autore), R. V. Orlova (Autore), M. A. Mukhina (Autore)
• Natura: Libro
• Pubblicazione: ABV-press, 2021-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

The emergence of a new class of drugs - inhibitors of cyclin-dependent kinases 4/6 (CDK4/6) - has changed the paradigm of treatment of patients with luminal HER2 negative metastatic breast cancer. Their effectiveness is confirmed not only by randomized, but also observational studies on a wide heter...